Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →In a four-week, double-blind, placebo-controlled Phase 2 trial of 245 patients with acute exacerbation of schizophrenia, ulotaront (SEP-363856) at 50 or 75 mg…
Otsuka has agreed to pay Sunovion $270 million upfront, plus undisclosed development and commercial milestones and profit splits, for a worldwide collaboration…
The U.S. Food and Drug Administration today approved Cobenfy (xanomeline and trospium chloride), a first-in-class oral medication for the treatment of…
Source summaries from our enrichment pipeline; follow links for originals.
All 15 sources with sentiment breakdown →
On September 30, 2021, Sunovion and its parent Sumitomo Dainippon Pharma entered a worldwide development and commercialization collaboration with Otsuka covering four psychiatry/neurology compounds: ulotaront (SEP-363856), a Phase 3 TAAR1/5-HT1A agonist for schizophrenia; SEP-4199 (bipolar I depression); SEP-378614; and SEP-380135. Otsuka paid Sunovion $270M upfront and the partners shared development costs and profits in designated regions, with up to $620M in development milestones plus sales milestones (total disclosed value ~$890M+). In July 2023 the Phase 3 DIAMOND 1 and DIAMOND 2 schizophrenia trials missed their primary endpoints, which the companies attributed to a high placebo response. On March 15, 2024 the parties amended the agreement: Otsuka took exclusive worldwide rights to develop, manufacture and commercialize ulotaront and SEP-380135 (with Otsuka bearing study costs from January 2024 and paying up to ~$30M in milestones plus royalties, no upfront), while SEP-4199 and SEP-378614 were excluded as Sumitomo refocused on oncology and regenerative medicine. Otsuka has since relaunched a Phase 3 schizophrenia study (NCT06894212) and continues ulotaront programs in major depressive disorder and generalized anxiety disorder.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sumitomo Dainippon Pharma Co., Ltd. / Otsuka Pharmaceutical Co., Ltd. (this deal) | 2021 | $270M | — |
| Sumitomo Dainippon Pharma Co., Ltd. / Cynapsus Therapeutics Inc. | 2016 | $624M | 28 |
| Sumitomo Dainippon Pharma Co., Ltd. / Tolero Pharmaceuticals, Inc. | 2016 | $780M | 24 |
| Sumitomo Dainippon Pharma Co., Ltd. / Roivant Sciences Ltd. (Sumitovant five-Vant deal) | 2019 | $3.0B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
← Browse all deals · How we score deals
More: 2021 deals · Sumitomo Dainippon Pharma Co., Ltd. deals · Neurology deals